Saira Ramasastry - Sep 8, 2025 Form 4 Insider Report for Mirum Pharmaceuticals, Inc. (MIRM)

Role
Director
Signature
/s/ Judit Ryvkin, Attorney-in-Fact
Stock symbol
MIRM
Transactions as of
Sep 8, 2025
Transactions value $
$399,670
Form type
4
Date filed
9/10/2025, 05:50 PM
Previous filing
Jun 4, 2025
Next filing
Nov 7, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Ramasastry Saira Director C/O MIRUM PHARMACEUTICALS, INC., 989 E HILLSDALE BLVD., SUITE 300, FOSTER CITY /s/ Judit Ryvkin, Attorney-in-Fact 2025-09-10 0001547959

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MIRM Common Stock Options Exercise $400K +17K $23.51 17K Sep 8, 2025 Direct
transaction MIRM Common Stock Sale -17K -100% 0 Sep 8, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MIRM Stock Option (right to buy) Options Exercise $0 -17K -50% $0.00 17K Sep 8, 2025 Common Stock 17K $23.51 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The weighted average sale price for the transaction reported was $77.042178, and the range of prices were between $76.835 and $77.29. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F2 The stock option is fully vested.